MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
BioMimetic losses widen 60 percent
BioMimetic Therapeutics Inc. (NSDQ:BMTI) reported losses of $10.0 million, or 36 cents per diluted share, on sales of $393,493 during the three months ended Dec. 31. That compares with profits of $1.1 million, or 5 cents per diluted share, on sales of $444,719 during the same period in 2009.
Full-year losses were $33.9 million, or $1.38 per diluted share, on sales of $1.5 million. That compares with losses of $21.2 million, or $1.03 per diluted share, on sales of $1.6 million in 2009.
Read more
Cantel’s annual profits shrink despite big Q4
Cantel Medical Corp. (NYSE:CMN) reported profits of $5.7 million or 33 cents per diluted share, on sales of $81.0 million during the three months ended Jan. 31. That compares with profits of $4.9 million, or 29 cents per diluted share, on sales of $66.6 million during the same period last year.
Full-year profits were $10.7 million, or 62 cents per diluted share, on sales of $153.0 million. That compares with profits of $11.0 million, or 65 cents per diluted share, on sales of $137.6 million in the year ending Jan. 31 2010.
Read more
Orthovita annual, Q4 losses widen
Orthovita Inc. (NSDQ:VITA) reported net losses of $3.9 million, or 5 cents per deluted share, on sales of $23.4 million during the three months ended Dec. 31. That compares with losses of $291,000, or less than 1 cent per share, on sales of $24.4 million during the same period in 2009.
Full-year losses were $5.7 million, or 7 cents per diluted share, on sales of $94.7 million. That compares with losses of $3.9 million, or 5 cents per diluted share, on sales of $92.9 million in 2009.
Read more
Cardiogenesis losses ease after sales bump
Cardiogenesis Corp. (OTC:CGCP) reported losses of $558,000 or 1 cent per diluted share, on sales of $2.9 million during the three months ended Dec. 31. That compares with profits of $409,000 million, or 1 cent per diluted share, on sales of $3.1 million during the same period last year.
Full-year losses were $1.3 million, or 3 cents per diluted share, on sales of $11.3 million. That compares with losses of $1.2 million, or 3 cents per diluted share, on sales of $10.4 million in 2009.
Read more
Transgenomic losses widen after 10 percent sales drop
Transgenomic Inc. (OTC:TBIO) reported a loss of $767,000, or 2 cents per diluted share, on revenue of $5.1 million during the three months ended Dec. 31. That compares with a profit of $129,000, or less than 1 cent per diluted share, on revenue of $6.5 million during the same period in 2009.
Full-year losses were $3.1 million, or 6 cents per diluted share, on revenue of $20.0 million. That compares with a loss of $1.9 million, or 4 cents per diluted share, on revenue of $22.0 million in 2009.
Read more
Synergetics sees small sales and income increases
Synergetics USA Inc. (NSDQ:SURG) reported profits of $1.3 million, or 5 cents per diluted share, on sales of $13.3 million during the three months ended Jan. 31. That compares with a profit of $877,000 million, or 4 cents per diluted share, on sales of $13.0 million during the same period last year.
Read more
Angeion losses more than halve on increased revenue
Angeion Corp. (NSDQ:ANGN) reported losses of $324,000, or 9 cents per diluted share, on sales of $7.1 million during the three months ended Jan. 31. That compares with a losses of $826,000, or 20 cents per diluted share, on sales of $6.6 million during the same period last year.
Read more
Zynex reports mixed results
Zynex Inc. (OTC:ZYXI) reported profits of $350,000, or 1 cent per diluted share, on sales of $24.1 million during the 12 months ended Dec. 31. That compares with profits of $2.4 million or 8 cents per diluted share, on sales of $18.7 million last year.
Read more
